Table 2.
Case 1 (17) | Case 2 (18) | Case 3 (19) | Case 4 (Present case) | |
---|---|---|---|---|
Male/Female | male | male | male | male |
Age | 55 | 68 | 50 | 75 |
Primary disease | MM | MM | MM | NSCLC |
Dosage (/kg) | 2 mg/3 w | 2 mg/3 w | 2 mg/3 w | 3 mg/2 w |
Cycles of nivolumab therapy | 4 | ND | 6 | 12 |
Time after nivolumab initiation | 12 weeks | 28 weeks | 16 weeks | 23 weeks |
Radiographic pituitary enlargement | (-) | (-) | (+) | (-) |
Hyponatremia | (-) | ND | (+) | (+) |
Hypoglycemia | (-) | ND | (-) | (-) |
Hypotension | (+) | ND | ND | (+) |
Anterior pituitary dysfunction | ||||
TSH | (-)* | (-) | (+) | (-) |
ACTH | (+) | (+) | (+) | (+) |
LH/FSH | (-)* | (-) | (-) | (-) |
GH | (-)* | (-) | (-) | (-) |
PRL | (-)* | (-) | (+, elevated)** | (+, hyper-responsive) |
Posterior pituitary dysfunction | (-) | (-) | (-) | (-) |
MM: malignant melanoma, NSCLC: non-small-cell lung carcinoma, TSH: thyroid stimulating hormone, ACTH: adrenocorticotropic hormone, LH: luteinizing hormone, FSH: follicle-stimulating hormone, GH: growth hormone, PRL: prolactin, ND: not described,* diagnosed by basal hormone levels,** normal response in the stimulation test